Acro Biomedical Reports $10,301 Net Loss and No Revenue in Q1 2025

Acro Biomedical Co., Ltd. reported its financial results for the first quarter of 2025, revealing a net loss of $10,301, or $0.00 per share, compared to a net loss of $11,252, or $0.00 per share, for the same period in 2024. The company did not generate any revenue during the quarter, consistent with its performance in the previous year. Operating expenses for the quarter were $8,934, primarily related to public company expenses, while interest expenses to a minority stockholder amounted to $1,367.

The company's financial position showed a slight decrease in current assets, which fell to $4,851 from $5,076 at the end of 2024. Current liabilities increased marginally to $329,081 from $326,946, resulting in a working capital deficiency of $324,230, compared to $321,870 at the end of the previous year. Cash used in operating activities was $22,531, up from $13,513 in the prior year, reflecting the ongoing challenges in generating revenue and managing operational costs.

Acro Biomedical has not made any sales since December 31, 2022, and continues to rely on advances from a minority stockholder for funding. During the first quarter of 2025, the company received $22,306 in advances from this stockholder, compared to $13,288 in the same period of 2024. The company’s common stock is currently traded on the OTC Market Group’s Expert Market, which limits its marketability and raises concerns about its ability to secure additional financing.

The company has faced significant operational challenges, including the impact of COVID-19 restrictions in China, which have affected its customer base and sales potential. Acro Biomedical has no full-time employees, with its chief executive officer working part-time without compensation. The company has not developed any new products since its last sales and has not engaged in any significant research and development activities since August 2023.

Looking ahead, Acro Biomedical's management has expressed uncertainty regarding its ability to continue as a going concern, given its lack of revenue and minimal cash reserves. The company plans to seek funding through product sales and equity financing arrangements, but it currently has no orders for products and faces significant risks in executing its business plan. The financial statements reflect these uncertainties, as they do not include adjustments that might result from the outcome of this situation.